Altimmune, Inc. (ALT)
NASDAQ: ALT · Real-Time Price · USD
4.610
+0.080 (1.77%)
Feb 17, 2026, 1:53 PM EST - Market open
Altimmune Employees
Altimmune had 59 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
59
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$339
Profits / Employee
-$1,422,288
Market Cap
577.32M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 59 | 0 | - |
| Dec 31, 2023 | 59 | 7 | 13.46% |
| Dec 31, 2022 | 52 | 5 | 10.64% |
| Dec 31, 2021 | 47 | 4 | 9.30% |
| Dec 31, 2020 | 43 | 18 | 72.00% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| MeiraGTx Holdings | 409 |
| Lyell Immunopharma | 300 |
| Prime Medicine | 214 |
| ProKidney | 204 |
| Vor Biopharma | 154 |
| Lexicon Pharmaceuticals | 103 |
| Neumora Therapeutics | 95 |
| CorMedix | 65 |
ALT News
- 14 days ago - Obesity stocks slump on Novo's underwhelming 2026 sales forecast - Reuters
- 18 days ago - Altimmune Announces Closing of $75 Million Registered Direct Offering of Common Stock - GlobeNewsWire
- 19 days ago - Altimmune (ALT) Shares Slide On $75 Million Stock Offering - Benzinga
- 20 days ago - Altimmune Announces Pricing of $75 Million Registered Direct Offering of Common Stock - GlobeNewsWire
- 6 weeks ago - Altimmune Receives FDA Breakthrough Therapy Designation for Pemvidutide in MASH - GlobeNewsWire
- 7 weeks ago - Altimmune: Pemvidutide's 48-Week Data Confirms The Market's Smokescreen - Seeking Alpha
- 2 months ago - Altimmune's MASH Drug Shows Durable Liver, Weight Loss Gains At 48 Weeks - Benzinga
- 2 months ago - Altimmune, Inc. (ALT) Discusses Topline 48-Week Results From IMPACT Phase IIb Trial of Pemvidutide in MASH Transcript - Seeking Alpha